# FDA Approves Vertex's Casgevy Gene Therapy for Young Children with Sickle Cell Disease

> fda · REPORTED · 2026-07-01

On July 1, 2026, the FDA approved Vertex Pharmaceuticals' Casgevy as the first gene therapy approved for young children with sickle cell disease, marking a historic pediatric expansion of the CRISPR-based therapy. This milestone broadens the eligible patient population for the treatment.

About Vertex Pharmaceuticals: Vertex Pharmaceuticals is a global biotechnology company and a leader in cystic fibrosis therapeutics, also commercializing gene editing therapies including Casgevy (developed with CRISPR Therapeutics) for sickle cell disease and beta thalassemia.

- Company: Vertex Pharmaceuticals
- Sector: genomics
- Primary source: https://www.rttnews.com/3674019/biotech-stocks-facing-fda-decision-in-august-2026.aspx

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.